A preliminary trial, conducted at Massachusetts General Hospital is showing promise against many different tumor types. Known as ulixertinib, the drug was administered to 135 cancer patients who had failed treatments for a variety of advanced, solid tumors. According to the trial, ulixertinib "inhibits the MAPK/ERK pathway...a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell."
To read more about this trial, click here
No comments:
Post a Comment